Physician profile
Maria E Lamothe
NPI 1396929295
$39,996.81
in general payments reported to CMS, 2019-2025
56 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $3,789 · 2021: $2,694 · 2022: $630 · 2023: $1,475 · 2024: $1,618 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,472 · Gift: $59.40 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,471.61 |
| Gift | $59.40 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $27,333.46 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $3,858.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $2,643.51 | 2019-2020 | |
| Lilly USA, LLC | $514.09 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $426.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.03 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $403.67 | 2019-2025 | Freestyle Libre |
| Mannkind Corporation | $304.75 | 2019-2024 | Afrezza |
| Amgen INC. | $300.05 | 2019-2025 | Prolia, Evenity, Prolia |
| Intuity Medical INC | $270.57 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Insulet Corporation | $261.38 | 2019-2025 | Omnipod |
| Radius Health, INC. | $251.54 | 2019-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $233.34 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $214.91 | 2019-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $171.71 | 2019-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $151.12 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $146.27 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $142.15 | 2019-2025 | Korlym |
| Cequr Corporation | $137.24 | 2021-2025 | Cequr Simplicity |
| Medtronic, INC. | $134.81 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Kerecis Limited | $129.14 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Beta Bionics, INC. | $112.03 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $104.03 | 2019-2025 | Unithroid |
| Pfizer INC. | $98.20 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $94.72 | 2023-2025 | Isturisa, Signifor Lar |
| Medtronic Minimed, INC. | $81.48 | 2019 | |
| Valeritas, INC. | $78.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.18 | 2025 | |
| Shire North American Group INC | $70.33 | 2019 | |
| Antares Pharma, INC. | $65.65 | 2019-2025 | Xyosted |
| Ibsa Pharma INC. | $60.68 | 2019-2025 | Tirosint, Licart, Tirosint |
| Vivus LLC | $60.58 | 2019-2022 | |
| Lifescan, INC. | $57.70 | 2019-2020 | |
| Tolmar, INC. | $52.93 | 2024-2025 | Jatenzo |
| Acella Pharmaceuticals, LLC | $48.71 | 2024-2025 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $37.95 | 2024-2025 | Strensiq |
| Neurocrine Biosciences, INC. | $37.81 | 2025 | |
| Sequel Med Tech, LLC | $37.54 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $35.52 | 2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $33.00 | 2022-2023 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $32.63 | 2024 | Imcivree |
| Currax Pharmaceuticals LLC | $31.90 | 2025 | Contrave |
| Amarin Pharma, INC. | $29.99 | 2020-2021 | |
| Becton, Dickinson and Company | $29.32 | 2020-2021 | |
| Astellas Pharma US INC | $21.51 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $21.37 | 2025 | |
| Madrigal Pharmaceuticals | $19.21 | 2025 | Rezdiffra |
| Soleno Therapeutics, INC. | $17.17 | 2025 | Vykat Xr |
| Esperion Therapeutics, INC. | $14.98 | 2021 | |
| Clarus Therapeutics INC. | $14.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.76 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.73 | 2019 | |
| Sanofi Pasteur INC. | $13.64 | 2019 | |
| Verity Pharmaceuticals INC. | $13.38 | 2024 | Tlando |
| Amryt Pharma Holdings Ltd | $12.79 | 2022 | |
| Eisai INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lamothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.